The progression of pancreatic oncogenesis requires immune-suppressive inflammation in cooperation with oncogenic mutations. However, the drivers of intratumoral immune tolerance are uncertain. Dectin 1 is an innate immune receptor crucial for anti-fungal immunity, but its role in sterile inflammation and oncogenesis has not been well defined. Furthermore, non-pathogen-derived ligands for dectin 1 have not been characterized. We found that dectin 1 is highly expressed on macrophages in pancreatic ductal adenocarcinoma (PDA). Dectin 1 ligation accelerated the progression of PDA in mice, whereas deletion of Clec7a-the gene encoding dectin 1-or blockade of dectin 1 downstream signaling was protective. We found that dectin 1 can ligate the lectin galectin 9 in mouse and human PDA, which results in tolerogenic macrophage programming and adaptive immune suppression. Upon disruption of the dectin 1-galectin 9 axis, CD4 + and CD8 + T cells, which are dispensable for PDA progression in hosts with an intact signaling axis, become reprogrammed into indispensable mediators of anti-tumor immunity. These data suggest that targeting dectin 1 signaling is an attractive strategy for developing an immunotherapy for PDA.
a r t i c l e s PDA is a devastating disease with few long-term survivors 1 . Inflammation is paramount in PDA progression; oncogenic mutations alone, in the absence of concomitant inflammation, are insufficient for tumorigenesis 2 . Innate and adaptive immunity cooperate to promote tumor progression in PDA. In particular, specific innate immune subsets in the tumor microenvironment (TME) are apt at educating adaptive immune effector cells toward a tumorpermissive phenotype. Some antigen-presenting cell (APC) populations, including M2-polarized tumor-associated macrophages (TAMs) and myeloid dendritic cells (DCs), induce the generation of immune-suppressive type-2 helper T (T H 2) cells rather than of proinflammatory type-1 helper T (T H 1) cells 3, 4 . Similarly, we and others have shown that myeloid-derived suppressor cells (MDSCs) negate anti-tumor CD8 + cytotoxic T lymphocyte (CTL) responses in PDA and promote metastatic progression [5] [6] [7] . However, the drivers of monocytic cellular differentiation toward an immune-suppressive phenotype remain uncertain. Dectin 1, encoded by CLEC7A, is a member of the C-type lectin family of pattern-recognition receptors and is expressed on the surface of macrophages and other cells of the myeloid-monocytic lineage 8 . Dectin 1 is a crucial component of the innate immune system's ability to recognize β-glucan polysaccharides derived from fungal cell walls 9 . Ligation of dectin 1 by β-glucans phosphorylates spleen tyrosine kinase (Syk), recruits the CARD9 adaptor protein, and thereby initiates an anti-fungal immune response 10, 11 . Our recent work suggested that chronic inflammatory injury upregulates dectin 1 expression in the liver 12 . Furthermore, we found that the PDA TME is rife with damage-associated molecular patterns (DAMPs), generated as by-products of inflammation and necrotic cell death 3, 13 . However, unlike Toll-like receptors, which influence oncogenic progression when ligated by DAMPs 3, 14, 15 , the role of dectin 1 in non-pathogenmediated inflammation or oncogenesis is not well defined, and sterile dectin 1 ligands have not been characterized. We discovered high dectin 1 expression and the presence of novel dectin 1 agonists within the PDA TME. We postulated that dectin 1 ligation in macrophages drives their immune-suppressive cellular differentiation in PDA and thereby governs the tolerogenic T cell program in the TME, which facilitates oncogenic progression.
RESULTS

High dectin 1 expression in mouse and human PDA
To test the relevance of dectin 1 signaling to PDA, we examined dectin 1 expression in two mouse models of PDA: a slowly progressive model, Ptf1a Cre ;Lox-Stop-Lox (LSL)-Kras G12D (KC), in which mice express oncogenic Kras in their pancreatic progenitor cells, and a more aggressive, orthotopic model of PDA using tumor cells from Pdx1 Cre ;LSL-Kras G12D ;Trp53 R172H (KPC) mice, which express mutated Kras and Trp53. We also examined its relevance in human PDA. Immunohistochemical (IHC) analysis indicated high dectin 1 expression in leukocytes from KC mice pancreata and in transformed epithelial cells ( Fig. 1a and Supplementary Fig. 1a,b) . Pancreata from KC mice crossed with dectin-1-double-negative (KC;Clec7a −/− ) animals served as controls. Flow cytometry revealed ~2-fold higher dectin 1 expression in macrophages (46%), neutrophils and inflammatory monocytes (80%) and DCs (65%) within the KC TME as compared to their cellular counterparts in spleen (18%, 47% and 40%, respectively) ( Fig. 1b) . Similarly, in orthotopically implanted KPC tumors, dectin 1 was highly expressed on leukocytes and in malignant epithelial cells ( Fig. 1c and Supplementary Fig. 1c-e ). Dectin 1 was also expressed at higher levels in leukocytes in PDA (44%) as compared to those in normal pancreas (9%) (Fig. 1d) . Immunofluorescence microscopy of human PDA similarly indicated high dectin 1 expression in transformed epithelial cells and in tumorinfiltrating myeloid cells ( Supplementary Fig. 1f,g) . In parallel to those in mice, human PDA-infiltrating CD14 + and CD15 + monocytes and macrophages and CD11c + DCs expressed higher levels of dectin 1 as compared to their cellular counterparts in peripheral blood mononuclear cells (PBMCs) (Fig. 1e) .
To investigate the stimulus for the upregulation of dectin 1 expression in leukocytes in PDA, we co-cultured bone marrow-derived macrophages (BMDMs) with pancreatic tumor cells derived from KPC mice. PDA cells and PDA cellular supernatant upregulated dectin 1 expression in BMDMs; however, select cytokines associated with PDA did not influence dectin 1 expression ( Supplementary  Fig. 1h ). Collectively, these results suggest that dectin 1 expression is upregulated in the tumor and peritumoral inflammatory compartments in PDA.
Evidence of dectin 1 signaling and the presence of dectin 1 ligands in PDA To investigate the relevance of dectin 1 signaling in pancreatic oncogenesis, we assayed 3-month-old and 6-month-old WT and KC mouse pancreata for the presence of activated signaling intermediates downstream of dectin 1 ligation. We found that, when compared to age-matched WT pancreata, KC pancreata expressed elevated levels of p-Syk and p-phospholipase C (PLC)-γ, as well as high CARD9 expression and evidence of robust c-Jun N-terminal kinase (JNK) pathway activation ( Supplementary Fig. 2a ). IHC analysis confirmed the presence of high p-Syk expression in KC pancreata, whereas Syk signaling was reduced in PDA in the context of dectin 1 deletion (Supplementary Fig. 2b) . Similarly, flow cytometry showed elevated p-Syk expression in diverse myeloid cellular subsets in PDA, as compared to their counterparts in the spleen (Supplementary Fig. 2c ).
To investigate whether dectin 1 ligands were present in the pancreatic TME, we employed a human IgG Fc-conjugated dectin 1 fusion protein. Whereas dectin 1 ligands were absent in WT pancreata, we identified high levels of dectin 1 ligands in the pancreata of KC mice, as measured by western blotting (Supplementary Fig. 2a ) and immunofluorescence microscopy ( Supplementary Fig. 2d ). Flow cytometric analysis confirmed the expression of dectin 1 ligands on tumor-infiltrating macrophages and DC in KC pancreata as compared to no expression in leukocytes in spleen ( Supplementary  Fig. 2e ). The expression of dectin 1 ligands was similarly elevated in APCs infiltrating orthotopic KPC tumors ( Supplementary  Fig. 2f ). Furthermore, CD133 + -transformed epithelial cells in KC tumors (Supplementary Fig. 2g ) and KPC tumors ( Supplementary  Fig. 2h ) expressed dectin 1 ligands in vivo, as did KPC-derived tumor cells grown in culture ( Supplementary Fig. 2i ). Collectively, our data indicate high expression of the dectin 1 receptor and dectin 1 ligands in the epithelial and inflammatory compartments of PDA, along with upregulation of associated signaling intermediates.
Dectin 1 ligation accelerates pancreatic oncogenesis
Given that dectin 1 and its cognate ligands are highly expressed in PDA, we postulated that dectin 1 signaling might promote immunesuppressive inflammation, leading to accelerated tumorigenesis. To test this, we treated 6-week-old KC mice serially with the dectin-1specific agonists depleted zymosan (d-zymosan) or heat-killed Candida albicans (HKCA) and assessed tumor progression 8 weeks later by comparison to vehicle-treated animals. Ligation of dectin 1 vigorously accelerated tumorigenesis ( Fig. 1f-i) . Whereas pancreata in vehicle-treated KC mice harbored large areas of residually normal acinar architecture, mice treated with dectin 1 agonists exhibited near-complete effacement of their pancreatic acini with more advanced pancreatic intra-epithelial neoplasia (PanIN) lesions and numerous foci of invasive carcinoma embedded in dense fibroinflammatory stroma ( Fig. 1f-i) . Kras-transformed ductal epithelial cells in dectin-1-agonist-treated KC mice also exhibited elevated proliferative rates, as measured by Ki67 staining ( Supplementary  Fig. 3a) . Similarly, the administration of dectin 1 agonists in vivo accelerated tumor growth in orthotopically implanted, KPC-derived tumors (Fig. 1j) . These data suggest that dectin 1 signaling promotes the progression of PDA.
Clec7a deletion is protective against PDA To determine whether dectin 1 signaling is required for the normal progression of pancreatic oncogenesis, we examined the tumor-phenotype in KC;Clec7a −/− mice over time. Dectin 1 deletion delayed malignant progression and stromal expansion. As compared to KC controls, age-matched KC;Clec7a −/− pancreata exhibited delayed development of pancreatic dysplasia and fibrosis ( Fig. 2a and Supplementary Fig. 3b ) and extended survival ( Fig. 2b) . To determine whether dectin 1 deletion influences molecular oncogenesis, we probed pancreata from KC and KC;Clec7a −/− mice for select cell-cycle regulatory, oncogenic and tumor-suppressor genes. KC; Clec7a −/− pancreata exhibited higher expression of the tumor-modulatory genes encoding Bcl-xL, Rb, Smad4 and p16 but reduced p53 and c-Myc expression, which is indicative of a distinct oncogenic phenotype (Fig. 2c) . Collectively, these data imply that dectin 1 contributes to the normal progression of pancreatic neoplasia in the context of a driving Kras mutation.
Syk inhibition is protective against PDA Given that dectin 1 signals through Syk phosphorylation, and, as we showed, Syk activation is reduced in KC;Clec7a −/− pancreata, we postulated that Syk blockade would be protective against pancreatic oncogenesis. KC mice were treated from 6-14 weeks of life with piceatannol, a p-Syk inhibitor, and tested for tumor progression through comparison with vehicle-treated controls. We confirmed that piceatannol prevented Syk activation in vivo in PDA. Syk inhibition reduced pancreatic tumor weights and mitigated dysplastic changes in KC mice, but was not protective in KC;Clec7a −/− mice ( Fig. 2d,e ), which suggests that the blockade of signaling pathways downstream of dectin 1 might be an attractive therapeutic strategy in pancreatic oncogenesis. a r t i c l e s nature medicine VOLUME 23 | NUMBER 5 | MAY 2017
Dectin 1 does not have direct protumorigenic effects on transformed pancreatic ductal epithelial cells
To determine whether dectin 1 ligation has direct mitogenic or activating effects on transformed pancreatic epithelial cells, we treated KPC-derived tumor cells in vitro with the dectin 1 agonist d-zymosan. Dectin 1 ligation failed to induce proliferation or cytokine production in PDA tumor cells ( Supplementary Fig. 4a-c) . HKCA similarly failed to induce proliferation or cytokine production in KPC cells (data not shown). To further test whether dectin 1 has direct oncogenic or proinflammatory effects in PDA cells, we silenced dectin 1 expression in KPC-derived tumor cells using shRNA ( Supplementary  Fig. 4d ). However, knockdown of dectin 1 did not alter the growth rate of tumor cells in vivo ( Supplementary Fig. 4e ), which suggests that dectin 1 signaling in the transformed epithelial compartment is not crucial for the modulation of PDA. Similarly, transformed pancreatic ductal epithelial cells (PDECs) harvested from KC and KC;Clec7a −/− pancreata proliferated at equal rates in vitro (Supplementary Fig. 4f ) and in vivo (Supplementary Fig. 4g ).
Clec7a deletion in the extra-epithelial compartment alone is protective against oncogenesis Given that dectin 1 ligation or knockdown does not influence the proliferative capacity of transformed pancreatic epithelial cells, we postulated that dectin 1 deletion in the extra-epithelial compartment alone would be protective against PDA. To investigate this, WT and Clec7a −/− mice were challenged with orthotopic injections of KPC-derived tumor cells with intact dectin 1 expression. Pancreatic tumors harvested at 3 weeks were markedly smaller in Clec7a −/− hosts, Figure 2 Dectin 1 deletion or blockade is protective against PDA. (a) KC;Clec7a +/+ (n = 10) and KC;Clec7a −/− (n = 6) mice were killed at 3, 6 or 9 months of age. Representative H&E-stained sections are shown. The percentage of pancreatic area occupied by intact acinar structures and the fractions of ductal structures exhibiting normal morphology, ADM or graded PanIN I-III lesions were calculated. Scale bar, 200 µm. (b) Kaplan-Meier survival analysis was performed by comparing KC;Clec7a +/+ mice (n = 29) and KC;Clec7a −/− mice (n = 41) (P = 0.01, log-rank test). (c) Whole-pancreas lysates from 3-month-old KC;Clec7a +/+ and KC;Clec7a −/− mice were assayed for the expression of select oncogenic and tumor-suppressor genes. (d) 6-week-old KC;Clec7a +/+ (n = 10) and KC;Clec7a −/− (n = 5) mice were serially treated with the p-Syk inhibitor piceatannol or with vehicle for 8 weeks before euthanization. Pancreas weights were measured, and representative H&E-stained sections are shown. Scale bar, 200 µm. Each point represents data from a single mouse. (e) WT mice bearing orthotopic PDA were serially treated with the p-Syk inhibitor piceatannol or with vehicle for 3 weeks. Tumor-infiltrating APCs were extracted and tested for p-Syk expression by flow cytometry. Median fluorescence index (MFI) is shown (n = 5/group; data are means ± s.e.m; *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant by unpaired Student′s t-test). a r t i c l e s which suggests that Clec7a deletion in the extra-tumoral compartment alone is protective against PDA (Supplementary Fig. 4h ). Clec7a −/− mice also exhibited extended survival after orthotopic PDA tumor implantation, as compared to WT mice ( Supplementary  Fig. 4i ). Similarly, KC mice made chimeric using Clec7a −/− bone marrow were protected against oncogenesis when compared with KC mice made chimeric using WT bone marrow, which confirms that the deletion of dectin 1 in leukocytes alone is protective ( Supplementary  Fig. 4j ). Dectin 1 expression was not associated with adverse survival in the context of human PDA ( Supplementary Fig. 4k ); however, dectin 1 was a surrogate for total myeloid cell infiltration ( Supplementary Fig. 4l ).
Dectin 1 deletion induces immunogenic reprogramming of tumor-infiltrating macrophages
We speculated that the blockade of dectin 1 signaling in the stroma leads to protection against PDA by bolstering anti-tumor immunity. Specifically, we postulated that dectin 1 deletion leads to immunogenic reprogramming of macrophages, which results in reversal of the immune-suppressive phenotype of PDA-infiltrating T cells. To test this in vitro, we stimulated naive CD4 + and CD8 + T cells using CD3/CD28 co-ligation and measured the expression of inducible T cell costimulator (ICOS), CD44, IFN-γ and TNF-α, all of which were upregulated on activated T cells, and the expression of CD62L and IL-10, both of which were downregulated upon T cell activation. Clec7a +/+ or Clec7a −/− CD11b + cells harvested from KPC-derived tumors were added to select wells. Whereas tumor-infiltrating WT myeloid cells abrogated the upregulation of ICOS expression in α-CD3/CD28activated CD4 + and CD8 + T cells, PDA-infiltrating Clec7a −/− myeloid cells exhibited minimal inhibitory effects ( Fig. 3a,b) . Similarly, whereas WT CD11b + cells prevented CD4 + and CD8 + T cell adoption of a CD44 + CD62L − effector-memory phenotype in response to CD3/CD28 ligation, Clec7a −/− cells were noninhibitory ( Fig. 3c,d) . Moreover, in contrast to tumor-infiltrating WT CD11b + cells, which promoted IL-10 production from CD4 + T cells ( Fig. 3e) and negated IFN-γ and TNF-α expression in CD8 + T cells ( Fig. 3f) , Clec7a −/− cells only minimally induced IL-10 production in CD4 + T cells and were permissive of CD8 + cytotoxic T cell activation ( Fig. 3e,f) . Similar differential effects on CD4 + and CD8 + T cell inhibition were observed when we used purified Gr1 − CD11c − CD11b + F4/80 + PDA-associated macrophages (TAMs) harvested from WT hosts and compared them to TAMs harvested from Clec7a −/− hosts ( Supplementary Fig. 5a,b) . Conversely, the T cell inhibitory capacity of Gr1 + CD11b + neutrophils and inflammatory monocytes was not diminished in the context of dectin 1 deletion, which suggests that whereas dectin 1 signaling in TAMs affects their capacity to influence T cell differentiation, dectin 1 signaling in neutrophils and inflammatory monocytes does not affect their capacity to suppress T cell function ( Supplementary Fig. 5c ).
To investigate whether dectin 1 signaling promotes macrophagemediated immune-suppression in situ in PDA, we assessed macrophage recruitment and phenotype in both our slowly progressive (KC) and invasive (KPC) models of PDA in the contexts of either dectin 1 deletion or dectin 1 activation. KC;Clec7a −/− mice exhibited significantly reduced pancreatic infiltration with F4/80 + and Arg1 + TAMs on IHC analysis ( Fig. 4a,b) . Flow cytometry confirmed a ~50% reduction in the fraction of TAMs in KC;Clec7a −/− pancreata ( Fig. 4c) . We found a similar decrease in the fraction of TAMs in orthotopic KPC tumors in Clec7a −/− hosts as compared to the WT (Fig. 4d) . Accordingly, analysis of orthotopic KPC tumors using a PCR array suggested reduced expression of diverse inflammatory mediators in tumors in Clec7a −/− hosts as compared to WT (Supplementary Fig. 5d ). Moreover, cellular-phenotyping experiments indicated that dectin 1 deletion induced immunogenic reprogramming of TAMs toward M1-like differentiation. Specifically, TAMs infiltrating Clec7a −/− pancreata expressed elevated major histocompatibility complex (MHC) II, reduced levels of CD206 and higher levels of TNF-α and iNOS than Clec7a +/+ hosts, which is suggestive of M1-like programming ( Fig. 4e-g) . By contrast, the prevalence and immune phenotype of Experiments were repeated more than three times with similar results. (l) Clec7a −/− mice were subcutaneously implanted with KPC-derived PDA tumor cells admixed with WT or Clec7a −/− macrophages. Tumor volume was recorded at serial intervals. This experiment was repeated twice with similar results (n = 4/group; data are mean ± s.e.m; *P < 0.05; **P < 0.01; ****P < 0.0001; n.s., not significant by unpaired Student's t-test).
a r t i c l e s 5 6 2 VOLUME 23 | NUMBER 5 | MAY 2017 nature medicine CD11c + MHCII + DCs were similar in both WT and Clec7a −/− PDA tumors ( Supplementary Fig. 5e,f) . We confirmed that exogenous dectin 1 ligand administration using d-zymosan activates Syk signaling in the PDA TME (Fig. 4h) . Accordingly, dectin 1 ligation in vivo increased the fraction of TAMs in orthotopic KPC tumors ( Fig. 4i ) and upregulated CD206 expression ( Fig. 4j) ; however, MHC II expression was not significantly altered (Fig. 4k) . Similar effects on macrophage programming were seen after treatment in vivo with HKCA (data not shown). Moreover, adoptive transfer of WT macrophages coincident with PDA tumor challenge in Clec7a −/− hosts resulted in an accelerated tumor growth rate as compared to adoptive transfer of Clec7a −/− macrophages ( Fig. 4l) .
Dectin 1 signaling suppresses T cell immunogenicity in a mouse model of PDA
On the basis of macrophage phenotyping and adoptive-transfer experiments, as well as our co-culture data from in vitro experiments, we postulated that the reprogramming of TAMs resulting from dectin 1 deletion in PDA leads to enhanced immunogenicity in tumorentrained T cells. To test this, we interrogated the T cell phenotype in pancreas-draining lymph nodes in KC and KC;Clec7a −/− mice, as well as in orthotopic KPC tumors in WT and Clec7a −/− hosts. Consistent with our hypothesis, dectin 1 deletion in KC mice led to immunogenic reprogramming of tumor-draining CD4 + and CD8 + T cells, which exhibited upregulated expression of CD44, OX40 and PD-1, indicative of cellular activation (Fig. 5a-c) . Dectin 1 deletion also increased the CD8:CD4 ratio in tumor-draining lymph nodes (Fig. 5d) . Similarly, dectin 1 deletion increased the CD8:CD4 ratio in tumor-infiltrating T cells in orthotopic KPC tumors (Fig. 5e) . Furthermore, CD8 + T cells in KPC tumors in Clec7a −/− hosts exhibited an activated phenotype with high expression of PD-1, TBX21 (T-bet), TNF-α, CD107a, and granzyme B, which points to enhanced CD8 + T cell cytotoxic potential, as compared to that in orthotopic KPC tumors in WT hosts (Fig. 5f) . Accordingly, orthotopic administration of KPC cells engineered to express ovalbumin (OVA) resulted in a markedly higher fraction of tumor-infiltrating, OVA-pentamer-positive cytotoxic T cells in Clec7a −/− hosts as compared to WT (Supplementary Fig. 5g,h) . Similarly, PDA-infiltrating CD4 + T cells in Clec7a −/− hosts expressed higher levels of CD44, CD107a and ICOS and exhibited enhanced T H 1 polarization, as evidenced by upregulated expression of T-bet and TNF-α ( Fig. 5g) . Collectively, these data indicate enhanced T cell immunogenicity. Notably, in agreement with higher T cell activation and PD-1 expression detected in PDA tumors in Clec7a −/− mice, dectin 1 deletion in combination with PD-1 blockade tended to offer synergistic protection and further enhanced intratumoral T H 1 polarization, whereas PD-1 blockade had no efficacy in the absence of dectin 1 deletion (Fig. 5h,i) .
We postulated that exogenous dectin 1 ligation would induce an immune-suppressive T H 2 phenotype and reduce CD8 + T cell activation. Accordingly, CD4 + T cells harvested from d-zymosan-treated, KPCtumor-bearing mice exhibited reduced T-bet and TNF-α expression but higher IL-5, IL-10 and IL-13 expression, as compared to vehicletreated, tumor-bearing mice (Supplementary Fig. 6a) . Similarly, CD8 + T cells exhibited diminished T-bet and TNF-α expression after dectin 1 ligation (Supplementary Fig. 6b ). Furthermore, macrophage depletion in vivo activated PDA-infiltrating CD4 + and CD8 + T cells exclusively in WT hosts, and not in Clec7a −/− hosts, which suggests that dectin-1-expressing macrophages drive T cell suppression in PDA (Supplementary Fig. 6c,d) .
To test definitively whether tumor protection in the absence of dectin 1 signaling is contingent on immunogenic T cell reprogramming, we depleted T cells coincident with orthotopic KPC tumor administration in cohorts of WT and Clec7a −/− animals. Pan-T cell depletion did not affect PDA growth in WT mice; however, tumor protection was abrogated in Clec7a −/− cohorts ( Supplementary  Fig. 6e) . Similarly, CD4 + and CD8 + T cell depletion alone each reversed tumor protection in Clec7a −/− mice Supplementary  Fig. 6f,g) , but not in WT mice (data not shown). These data suggest that in PDA-bearing WT hosts, T cells are dispensable to outcome; conversely, in the absence of dectin 1 signaling, T cells are reprogrammed into indispensable mediators of tumor protection.
Galectin 9 ligates dectin 1 in PDA Non-pathogen-derived dectin 1 ligands have not been well characterized. Therefore, we performed affinity purification-mass spectrometry, using the IgG Fc-conjugated dectin 1 fusion protein coupled to protein-G beads, to purify putative ligand(s) in KPC tumor extracts. The proteins co-purified with the dectin 1 fusion protein were contrasted with proteins purified with protein-G beads alone. Affinity purification coupled with mass spectrometry experiments were repeated twice, and only proteins that uniquely co-purified with the IgG Fc-conjugated dectin 1 fusion protein were considered as possible candidate dectin 1 ligands. A total of 19 proteins were identified.
Among the co-purified proteins was galectin 9 (Supplementary Table 1 ). Given that galectin 9 is a member of the β-galactoside-binding family of lectins, we hypothesized that galectin 9 is a sterile ligand for dectin 1. We assayed for the presence of galectin 9 in the mouse PDA TME and found robust expression of galectin 9 in diverse PDAinfiltrating myeloid cells and in cancer cells by flow cytometry (Fig.  6a,b) . We also found modest expression of galectin 9 in both leukocytes (13%) and tumor cells (7%) in human PDA, whereas galectin 9 was minimally expressed in leukocytes in PBMCs (Fig. 6c) . We further demonstrated the expression of galectin 9 in PDA-infiltrating leukocytes and cancer cells by confocal microscopy (Fig. 6d,e ). To investigate whether dectin 1 ligates galectin 9, protein-G magnetic beads were loaded with the dectin-1 IgG Fc-conjugated fusion protein or control IgG Fc. Bead-IgG Fc complexes were incubated with recombinant galectin 9 and then labeled with a fluorescently conjugated α-galectin 9 monoclonal antibody (mAb) and tested for fluorescence by flow cytometry. We found that the IgG Fc-conjugated dectin 1 fusion protein avidly ligated galectin 9, whereas controls failed to elicit a positive signal (Fig. 6f) . Furthermore, our data suggest that galectin 9 ligation of dectin 1 might be competitively inhibited by d-zymosan ( Fig. 6f) . Galectin 9 also bound mouse ( Fig. 6g) and human ( Fig. 6h ) dectin 1 in a dose-dependent manner in an enzyme-linked immunosorbent assay (ELISA). By contrast, mouse dectin 1 did not avidly bind galectin 3 or galectin 4 ( Fig. 6i) . We further confirmed that galectin 9 binds dectin 1 in situ by precipitating dectin 1 ligands in pancreatic tissue extract from KC mice and then probing for galectin 9. Our results indicated dectin 1-galectin 9-complex formation (Fig. 6j) . Given that galectin 9 binds to polylactosamine epitopes on glycoproteins, we assessed whether galectin 9 ligates dectin 1 through a glycan-galectin 9 interaction. To test this, we pretreated dectin 1 with PNGaseF, an enzyme that cleaves N-linked glycans, and tested whether this modulated the interaction. We observed no change in the binding affinity between the proteins, which suggested that galectin 9 ligation of dectin 1 is glycan independent (Fig. 6k) . In addition, we pretreated galectin 9 with high concentrations of lactose, a known inhibitor of galectins, before incubation with dectin 1. Again, no alteration of a r t i c l e s nature medicine VOLUME 23 | NUMBER 5 | MAY 2017 Cohorts were additionally treated with α-PD-1 or isotype control. Tumor weights were measured on day 21 (h), and the fraction of CD4 + T cells expressing IFN-γ was determined by flow cytometry (i); n = 5 mice/group. All experiments were repeated at least twice (data are mean ± s.e.m; *P < 0.05, **P < 0.01, ***P < 0.001; n.s., not significant by unpaired Student's t-test). a r t i c l e s the dectin 1-galectin 9 interaction was observed, which confirmed the idea of glycan-independent binding (Fig. 6k) . To determine whether galectin 9 is a functional dectin 1 ligand, we treated WT and Clec7a −/− macrophages with recombinant galectin 9 and measured Syk phosphorylation. Galectin 9 activated Syk in a dectin-1-dependent manner (Fig. 6l) . Similarly, galectin 9 induced nuclear factor (NF)-κB signaling in a dose-dependent manner in a human embryonic kidney (HEK) 293 dectin 1 reporter cell line 16 (Fig. 6m) . An irrelevant ligand specific for the C-type lectin receptor Mincle did not activate dectin 1 reporter cells (data not shown).
Galectin 9 blockade is protective against PDA Because we found that galectin 9 activates dectin 1 in PDA, we postulated that blockade of galectin 9 would protect against tumor progression. To test for competitive inhibition of galectin 9 binding with a well-characterized dectin 1 ligand, the bead-IgG Fc complexes were incubated with recombinant galectin 9 together with d-zymosan and then stained with fluorescently conjugated anti-galectin 9. This assay was repeated twice with similar results. (g,h) Galectin-9-coated ELISA plates were incubated with increasing doses of mouse (g) or human (h) dectin 1 IgG Fc or control IgG Fc. The galectin-9-bound dectin 1 IgG Fc was detected with anti-IgG-horseradish peroxidase (HRP). Averages of triplicates are shown. ELISA assays was repeated twice with similar results. (i) Galectin-3-coated, galectin-4-coated and galectin-9-coated ELISA plates were incubated with dectin 1 IgG Fc or control IgG Fc (2.5 µg/ml) in parallel. The galectin-bound dectin 1 IgG Fc was detected with anti-IgG-HRP. Averages of triplicates are shown. (j) We precipitated dectin 1 ligands in pancreatic tissue extracts from 6-month-old KC mice using the dectin 1 IgG Fc or control IgG Fc and then probed for galectin 9 by western blotting. Recombinant galectin 9 was used as a positive control. This assay was repeated twice with similar results. (k) Dectin 1 IgG Fc was treated with either buffer or PNGase F, loaded onto protein-G beads and incubated with recombinant mouse galectin 9 preincubated with 100-mM lactose or buffer. Treated and control samples were analyzed by SDS-PAGE, and gels were stained with Coomassie blue. This experiment was repeated twice with similar results. (l) WT and Clec7a −/− macrophages were treated with galectin 9 (10 µg/ml) for 3 h. Syk phosphorylation was determined by flow cytometry and compared with isotype control. Representative histogram overlays and quantitative data from five separate experiments are shown. (m) Dectin 1 reporter HEK293 cells were untreated or treated with low or high doses of galectin 9 or the well-characterized dectin 1 ligands curdlan and d-zymosan. Dectin 1 activation was measured through the detection of secreted embryonic alkaline phosphatase. This assay was performed in triplicate (data are mean ± s.e.m; *P < 0.05; **P < 0.01; ****P < 0.0001; n.s., not significant by unpaired Student's t-test).
a r t i c l e s nature medicine VOLUME 23 | NUMBER 5 | MAY 2017 5 6 5 We found that serial treatment with a neutralizing galectin 9 mAb extended survival rates in mice harboring orthotopic KPC tumors (Supplementary Fig. 7a ). Galectin 9 blockade also extended survival after mAb treatment was initiated in mice that harbored established orthotopic KPC tumors (Supplementary Fig. 7b) . Similarly, elevated galectin 9 expression was associated with a trend toward reduced survival in the context of human PDA (Supplementary Fig. 7c) .
To determine whether galectin 9 blockade induces tumor regression, WT mice were implanted subcutaneously with PDA cells, and treatment with α-galectin 9 or an isotype was commenced after tumor development. Galectin 9 blockade resulted in substantial tumor regression (Supplementary Fig. 7d ). Furthermore, akin to dectin 1 deletion, combined blockade of galectin 9 and PD-1 trended to offer synergistic protection against orthotopic PDA (Supplementary Fig. 7e ) and resulted in enhanced T cell activation (data not shown). Moreover, T cell deletion abrogated the protective effects of galectin 9 blockade (Supplementary Fig. 7f) . By contrast, macrophage depletion was protective against PDA in WT hosts, as we have previously reported 13 ; however, the depletion of macrophages accelerated tumor growth in the context of galectin 9 neutralization (Supplementary Fig. 7f ). Furthermore, similarly to the deletion of dectin 1, galectin 9 neutralization was associated with immunogenic reprogramming of TAMs in PDA (Supplementary Fig. 7g) . These data suggest that galectin 9 neutralization leads to macrophagedependent adaptive anti-tumor immunity. Because galectin-9-based immunotherapy of orthotopic PDA tumors eventually fails-despite its ability to more than double median survival-we compared the cellular differentiation and inflammatory infiltrate in early (day 21) as opposed to late (day 42) tumors in mice treated with α-galectin 9. Tumor differentiation, macrophage infiltration and polarization were similar in early and late tumors (Supplementary Fig. 7h-j) . However, CD8 + T cell infiltration was markedly diminished in advanced tumors, and CD8 + T cells expressed lower amounts of IFN-γ and T-bet ( Supplementary Fig. 7k-m) .
To determine whether the immune-suppressive T cell program associated with dectin 1 signaling in the PDA TME was contingent on galectin 9, we serially blocked galectin 9 in KPC tumor-bearing WT mice and Clec7a −/− mice. Galectin 9 neutralization enhanced intratumoral T cell activation in PDA in WT hosts. However, galectin 9 neutralization failed to further activate the CD4 + or CD8 + T cells in the context of dectin 1 deletion ( Supplementary Fig. 8a,b) . Collectively, our data suggest that the dectin 1-galectin 9 axis plays a pivotal part in the education of CD4 + and CD8 + T cells toward immunogenic or tolerogenic phenotypes in PDA, which regulates oncogenic progression (Supplementary Fig. 8c) .
DISCUSSION
PDA is a devastating disease in which the mortality rate approaches the incidence rate 1 . PDA is almost invariably associated with a robust inflammatory infiltrate that can have divergent influences on disease progression by either combating cancer growth through antigen-restricted, tumoricidal immune responses or by promoting tumor progression through the induction of immune suppression [17] [18] [19] . For example, CD8 + T cells and T H 1-polarized CD4 + T cells mediate tumor protection in mouse models of PDA and are associated with prolonged survival in human disease 20 . Conversely, we and others reported that T H 2-polarized CD4 + T cells promote the progression of PDA in mice, and that intratumoral CD4 + T H 2 cell infiltrates are correlated with reduced survival rates in human disease 3, 20, 21 . Similarly, Foxp3 + regulatory T (T reg ) cells facilitate tumor immune escape and shorten survival in the context of PDA 22, 23 . Hence, T cell programming influences disease outcome in PDA. However, the mechanism of regulation of the balance between immunogenic and immune-suppressive T cell populations is uncertain. Our data suggest that dectin 1 signaling has a crucial role in the capacity of macrophages to educate CD4 + and CD8 + T cells toward immunogenic or tolerogenic phenotypes.
Dectin 1 is vital in the innate immune defense against fungal pathogens 24 . Patients with genetic deficiencies affecting dectin 1 are at risk for recurrent mucocutaneous fungal infections, such as vulvovaginal candidiasis or onychomycosis 25 . However, unlike their Toll-like receptor (TLR) cousins, a definitive role for dectin 1 in the promotion of non-pathogen-mediated inflammation or oncogenesis is lacking 26 . We previously reported that in the context of chronic liver disease in mice, dectin 1 signaling secondarily protects against the development of liver cancer by suppressing TLR4, which drives liver fibrosis and increases the associated risk of hepatocarcinogenesis development 12 . Additional evidence also suggests that, in select contexts, dectin 1 activation might bolster anti-tumor immunity. Chiba et al. 27 showed that dectin 1 expression on antigen-presenting cells is crucial to natural killer (NK)-cell-mediated killing of tumor cells that overexpress N-glycan structures. Dectin 1 recognition of these tumor cells leads to activation of the interferon regulatory factor 5 (IRF5) transcription factor, as well as the gene induction necessary to initiate tumoricidal activity of NK cells. Orally administered β-glucans might confer protection against lung and mammary tumors in mouse models of these diseases by ligating dectin 1 and inducing tumoricidal responses 28 . By contrast, we demonstrate that dectin 1 crucially regulates the macrophage phenotype in the context of PDA, which dictates the immunogenic or tolerogenic properties of peritumoral T cells. Moreover, we show that whereas T cell deletion does not influence tumor growth and thus T cells are dispensable to PDA, dectin 1 deletion renders T cells indispensable to tumor protection. These data suggest that targeting dectin 1 might be an attractive strategy for PDA immunotherapy in experimental therapeutics. We reported recently that the activation of Mincle, another C-type lectin receptor, also has protumorigenic properties 13 . However, unlike dectin 1, Mincle is a well-described death receptor and ligates by-products of necroptotic cell death within the PDA TME, including Sin3A-associated protein 130 (SAP130), which leads to expansion of the T reg cell population 13, 29 . Of note, we did not detect differential T reg cell expansion as a consequence of dectin 1 signaling in PDA (data not shown).
Interestingly, we found that, in addition to dectin 1 expression on peritumoral macrophages and myeloid cells, PDA cells also express dectin 1. However, the functional implications of the presence of dectin 1 in transformed epithelial cells seem to be inconsequential to tumorigenesis, because neither dectin 1 ligation nor dectin 1 knockdown in PDA cells influenced their proliferative or inflammatory properties, and neither condition affected tumor growth in vivo. Similarly, dectin 1 deletion in the inflammatory compartment alone is protective against PDA growth and extends mouse survival. These data were confirmed by our macrophage-adoptive-transfer experiments. This finding parallels our previous work investigating TLR4 or TLR9 signaling in PDA, which found that although these pattern-recognition receptors are highly expressed on tumor cells, receptor ligation does not directly influence tumor progression 3, 14 .
Beyond elucidating a crucial role for dectin 1 signaling in macrophages that contributes to the modulation of T cell plasticity in the transformed pancreas, one of the most important observations in this study is the discovery that galectin 9, a lectin with affinity for β-galactosides, a r t i c l e s is a functional ligand for dectin 1. Non-pathogen-derived ligands for dectin 1 have not been well described. Thus, these data might have far-reaching implications that suggest a broader role for dectin 1 in sterile inflammation and oncogenesis. Galectin 9 has been reputed to be an exhaustion ligand for the T cell immunoglobulin mucin receptor 3 (TIM3) checkpoint receptor on T cells 30 . TIM3 is also expressed on macrophages and dendritic cells 31 . However, the galectin 9-TIM3 relationship has recently been called into question 32 .
Galectin 9 has also recently been shown to bind CD137, wherein it facilitates receptor-complex aggregation, signaling and functional activity in lymphocytes and myeloid cells 33 . Hence, galectin 9 might have a broader role in immune regulation. However, we found that galectin 9 neutralization enhanced T cell activation only in Clec7a +/+ hosts, which suggests that galectin 9 exerts primary immune-suppressive effects specific to dectin 1 signaling. Of note, Martinez-Bosch et al. 34 reported recently that galectin 1 promotes PDA growth through stromal remodeling and Hedgehog-signaling activation, which suggests that other galectins also have a role in PDA progression. Additional reports have shown that galectin 1 contributes to tumor aggressiveness by promoting angiogenesis and T cell apoptosis, whereas the blockade of galectin 1 in vivo results in tumor rejection through the generation of tumor-specific, T cell-mediated responses 35, 36 . Conversely, galectin-3 ligation has been shown to activate tumor-infiltrating lymphocytes and promote anti-tumor immunity 37 . We found that other galectins did not avidly bind dectin 1, which thus implicates alternative mechanisms.
Our data suggest that, akin to dectin 1, galectin 9 would be an attractive target for immunotherapy in PDA. In contrast to our findings, galectin 9 has been reported to prevent metastases in models of colon cancer and melanoma by inhibiting the binding of tumor cells to extracellular-matrix components, which leads to the prevention of tumor cell migration 38 . There are also important limitations to targeting dectin 1 or galectin 9 to combat PDA because the tumors do eventually progress, according to our survival experiments in animal models. These data suggest that dectin-1-targeted or galectin-9-targeted immunotherapy would require additional treatments to achieve cure. Indeed, the complex network of immunosuppressive pathways present in tumors is unlikely to be overcome by intervention with a single immune-modulatory agent 39 . Acquired resistance to checkpoint-based immunotherapy by patients with melanoma has been associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation 40 . Relapse after immunotherapy has also been linked to upregulated expression of exhaustion ligands by tumors 41 . Our comparison of day-21 and day-42 PDA tumors in cohorts of mice treated with α-galectin 9 suggests that, eventually, CD8 + T cell-population expansion and activation fails. It is conceivable that the CD8 + T cells activated by interrupting the dectin 1-galectin 9 axis eventually become exhausted, as suggested by reduced IFN-γ and T-bet expression in day-42 tumors. In fact, our data suggest that immunotherapy regimens targeting PD-1 combined with therapies targeting either dectin 1 or galectin 9 are likely to have synergistic efficacy, wherein dectin 1 or galectin 9 blockade enhances T cell activation, and PD-1 blockade prevents exhaustion through checkpoint-receptor ligation. In agreement with our findings, a recent report suggested that durable regression of established tumors in melanoma requires concurrent immunotherapy with four distinct agents that target complementary aspects of innate and adaptive immunity 39 . Thus, the development of therapeutics targeting dectin 1 signaling will potentially produce immunotherapeutic options for human PDA.
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ONLINE METHODS
Animals and in vivo models. C57BL/6 (H-2Kb) mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and bred in-house. Clec7a −/− mice were a gift of G. Brown (University of Aberdeen, UK). KC mice (gift of D. Bar-Sagi) and KPC mice (gift of M. Philips, both New York University) develop pancreatic neoplasia endogenously by expressing mutant Kras alone or mutant Kras and Trp53, respectively, in the progenitor cells of the pancreas 42,43 . We previously detailed tumor progression and survival in control KC mice 44 . Clec7a −/− mice were crossed with KC mice to generate KC;Clec7a −/− animals. For orthotopic pancreatic tumor challenge, mice were administered intrapancreatic injections of either Kras G12D PDECs or FC1242 tumor cells derived from KPC mice. Kras G12D PDECs and FC1242 cells were generated as previously described 6, 14 .
In select experiments, we used KPC-derived tumor cells (1 × 10 6 ), which we engineered to express OVA using pCI-neo-cOVA (gift of M. Castro University of Michigan; Addgene plasmid #25097), as we have described 44 . Both male and female mice were used, but animals were sex-and age-matched in each experiment. For orthotopic tumor experiments, 8-10-week-old mice were used. No formal power analyses, randomization, exclusions or blinding were done. In preparation for intrapancreatic injection, cells were suspended in PBS with 50% Matrigel (BD Biosciences, Franklin Lakes, NJ) and 1 × 10 5 tumor cells were injected into the body of the pancreas through a laparotomy. Mice were killed 3 weeks later and tumor weights were recorded. In select experiments, KPCderived tumor cells (5 × 10 5 -10 × 10 5 total) were administered subcutaneously, alone or mixed with 2 × 10 5 macrophages. To study the effects of dectin 1 ligation, mice were administered d-zymosan (500 µg) or HKCA (5 × 10 7 cells; both Invivogen, San Diego, CA) by intraperitoneal (i.p.) injection five times weekly for 8 weeks in endogenous tumor models and for 3 weeks in the orthotopic tumor models. PDECs were harvested from the pancreata of KC mice and passaged in vitro, as previously described 6 . PDEC proliferation was measured using the XTT assay, according to the manufacturer's protocol (Roche, Nutley, NJ). In select experiments, cohorts of mice were treated five times weekly with the p-Syk inhibitor piceatannol (20 mg/kg, i.p.; Selleck Chemicals, Houston, TX). Pan-T cells (CD90, T24/31), CD4 T cells (GK1.5), CD8 T cells (53-6.72), and macrophages (F4/80, CI:A3-1, all BioXcell, West Lebanon, NH) were depleted with neutralizing mAbs using regimens that we have previously described 13, 45 . In other experiments, animals were treated twice weekly with an i.p. injection of neutralizing mAbs directed against PD-1 (29F.1A12, 6 mg/kg) or galectin 9 (RG9-1, 6mg/kg; both BioXCell), or respective isotype controls. Bone marrow chimeric animals were created by irradiating mice (9 Gy), followed by intravenous (i.v.) bone marrow transfer (1 × 10 7 cells) from nonirradiated donors, as we previously described 15 .
Chimeric mice were used in experiments 7 weeks later. All animal procedures were approved by the New York University School of Medicine Institutional Animal Care and Use Committee.
Cellular harvest and flow cytometry. Human or mouse single-cell suspensions for flow cytometry were prepared, as described previously 13 , with slight modifications. Briefly, pancreata were placed in cold RPMI 1640 with collagenase IV (1 mg/ml; Worthington Biochemical, Lakewood, NJ) and DNAse I (2 U/ml; Promega, Madison, WI) and minced with scissors to submillimeter pieces. Tissues were then incubated at 37 °C for 30 min with gentle shaking every 5 min. Specimens were passed through a 70-µm mesh and centrifuged at 350g for 5 min. The cell pellet was resuspended in cold PBS with 1% FBS. Single-cell splenocyte suspensions were prepared as previously described 13 . Cell labeling was performed after blocking FcγRIII/II with an anti-CD16/CD32 mAb (eBioscience, San Diego, CA) by incubating 1 × 10 6 cells with fluorescently conjugated Abs. The concentration of Abs was 2 µg/ml directed against murine CD44 (IM7), CD206 (C068C2), PD-1 (29F. Human PDA-infiltrating cells and PBMCs were stained with mAbs directed against CD45 (HI30), CD14 (HCD14), CD15 (W6D3), galectin 9 (9M1-3), and CD11c (3.9; all BioLegend). OVA-restricted CD8 + T cells were identified using an OVA-Pentamer (Proimmune, Oxford, UK). Dead cells were excluded from analysis using zombie yellow (BioLegend). Intracellular cytokine staining was performed using the Fixation/Permeabilization Solution Kit (BD Biosciences) for cytokines, transcription factors and granzyme B. Flow cytometry was carried out on the LSR-II flow cytometer (BD Biosciences). Data were analyzed using FlowJo v.10.1 (Treestar, Ashland, OR). BMDMs were prepared as previously described 46 . In select experiments IL-12 (0.1 ng/ml; R&D Systems, Minneapolis, MN), TNF-α (8 pg/ml; Cell Signaling, Beverly, MA), or TGF-β (0.2 ng/ml; BioLegend) were added to day-8 BMDM cultures for 24 h. Alternatively, BMDM were co-cultured with KPC-derived tumor cells (at a 50:1 ratio).
Histology, immunohistochemistry and microscopy. For histological analysis, pancreatic specimens were fixed with 10% buffered formalin, dehydrated in ethanol, embedded with paraffin and stained with H&E or Gomori's Trichrome. The fraction of preserved acinar area was calculated as previously described 13 . Pancreatic ductal dysplasia was graded according to established criteria 47 . IHC on frozen or paraffin-embedded mouse tissues was performed using antibodies directed against F4/80 (CI:A3-1, conc: 10 µg/ml), arginase 1 (Polyclonal, conc: 2 µg/ml), p-Syk (Polyclonal, conc: 10 µg/ml), Ki67 (Polyclonal, conc: 3 µg/ml) and dectin 1 (2A11, Conc: 5 µg/ml, all Abcam). For paraffin-embedded samples (F4/80, p-Syk, Ki67, arginase 1), samples were dewaxed in ethanol, followed by antigen retrieval with 0.01-M sodium citrate with 0.05% Tween. For frozen specimen (dectin 1), samples did not undergo antigen retrieval before incubation with the primary antibody. Immunofluorescence staining on frozen mouse tissues was performed using antibodies against dectin 1 (2A11; conc: 20 µg/ml, Abcam), CD45 (30-F11; conc: 6.25 µg/ml, BD Biosciences), CK19 (Troma-III; University of Iowa), CD68 (FA-11, conc: 5 µg/ml, Abcam), dectin 1 Fc (fc-mdec1a; InvivoGen), galectin 9 (Polyclonal; Conc: 20 µg/ml, Bioss) and DAPI (Vector Labs, Burlingame, CA). Immunofluorescence staining in human tissue was performed using antibodies against dectin 1 (Polyclonal; conc: 20 µg/ml, Abcam), CD11b (M1/70, conc: 5 µg/ml), Ep-CAM (G8.8; conc: 5 µg/ml, both BioLegend) and DAPI (Vector Labs, Burlingame, CA). Immunofluorescence images were acquired using the Zeiss LSM700 confocal microscope with ZEN 2010 software (Carl Zeiss, Thornwood, New York). All human tissues were collected using an Institutional Review Board-approved protocol, and donors of deidentified specimens gave informed consent. Sample sizes for human experiments were not determined on the basis of formal power calculations. Quantifications were performed by assessing ten high-power fields (HPF; 40×) per slide in a blinded manner.
